news
Bristol Myers Squibb aims to improve disability diversity in clinical trials
Bristol Myers Squibb is collaborating with non-profit organisation Disability Solutions on an initiative to increase diversity in clinical trials.
List view / Grid view
Bristol-Myers Squibb Company
news
Expansion of the global antibiotics market size
The global antibiotics market is set to increase at a CAGR of 4 percent to $62.06 billion, due to the rising prevalence of infectious diseases...
news
Type 2 diabetes drug provides significant benefits to type 1 diabetic patients
A study has found that a majority of patients with Type 1 diabetes who were treated with dapagliflozin, a Type 2 diabetes medicine, had a significant decline in their blood sugar levels...
news
Novartis & Bristol-Myers Squibb to collaborate on cancer treatments
7 June 2017 | By Niamh Marriott, Junior Editor
Novartis has entered into a research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist...
article
Formulation Development & Drug Delivery In-Depth Focus 2017
Understanding the effect of API changes in pharmaceutical processing; Improving the consistency of MDI drug delivery; and Expert Views with DDF Summit and Eurofins Lancaster Laboratories...
news
NICE recommends ‘breakthrough’ drug nivolumab for advanced renal cell cancer
21 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Nivolumab is an intravenous drug, a form of immunotherapy that works by harnessing the power of the patient’s own immune system to destroy the cancer cells...
news
NICE says CDF case for nivolumab to treat lung cancer is not clear cut
14 October 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE’s appraisal committee concluded that nivolumab was not cost-effective for all patients in the treatment of non small-cell lung cancer...
news
Scotland speeds ahead to deliver breakthrough immunotherapy to lung cancer patients
11 October 2016 | By Niamh Louise Marriott, Digital Content Producer
This recommendation means that patients in Scotland will become the first in the UK to be treated with nivolumab on the NHS...
news
‘Game-changing’ immunotherapy doubles head and neck cancer survival
10 October 2016 | By Niamh Louise Marriott, Digital Content Producer
An immunotherapy drug has been hailed as a ‘game changer’ after being found to greatly improve survival for patients with relapsed head and neck cancer...
news
Bristol-Myers Squibb and Nektar Therapeutics to combine oncology therapies
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Bristol-Myers' Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression and NKTR-214 is an immuno-stimulatory therapy...
news
SMC accepts five new medicines for use in NHS Scotland
11 July 2016 | By Victoria White, Digital Content Producer
The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib...
news
Bristol-Myers Squibb acquires Cormorant Pharmaceuticals
5 July 2016 | By Victoria White, Digital Content Producer
The acquisition gives Bristol-Myers Squibb full rights to Cormorant Pharmaceuticals' HuMax-IL8 antibody programme...
news
BMS and PsiOxus to evaluate Opdivo and enadenotucirev in cancer
1 July 2016 | By Victoria White, Digital Content Producer
The companies are to evaluate the safety, tolerability and efficacy of enadenotucirev and Opdivo in a range of tumour types in late-stage cancer patients...
news
BMS in sickle cell partnership to help treat Angolan children
27 June 2016 | By Victoria White, Digital Content Producer
The Angola Sickle Cell Initiative and Bristol-Myers Squibb are teaming up to provide children with sickle cell disease in Angola with Droxia...
news
NICE recommends nivolumab + ipilimumab for advanced melanoma
17 June 2016 | By Victoria White, Digital Content Producer
The NHS will receive a discount on the combination treatment agreed between Bristol-Myers Squibb and the Department of Health...
